Bridge Creek Capital Management LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 23,404 shares of the medical equipment provider’s stock after selling 140 shares during the quarter. Bridge Creek Capital Management LLC’s holdings in Zimmer Biomet were worth $3,747,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Freedman Financial Associates Inc. purchased a new position in Zimmer Biomet during the 4th quarter valued at about $25,000. Charter Oak Capital Management LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $27,000. Regent Peak Wealth Advisors LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $29,000. Birchcreek Wealth Management LLC purchased a new position in Zimmer Biomet during the 4th quarter valued at about $30,000. Finally, Exchange Traded Concepts LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter worth about $31,000. 87.17% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have commented on the stock. Evercore ISI raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and set a $175.00 price target for the company in a research note on Monday, January 4th. SVB Leerink lifted their price target on Zimmer Biomet from $185.00 to $190.00 and gave the stock an “outperform” rating in a research note on Monday, February 8th. Oppenheimer increased their price objective on Zimmer Biomet from $173.00 to $185.00 and gave the company an “outperform” rating in a research report on Monday, March 8th. Northland Securities upgraded Zimmer Biomet from a “market perform” rating to an “outperform” rating in a research report on Friday. Finally, JMP Securities increased their price target on shares of Zimmer Biomet from $165.00 to $180.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. Zimmer Biomet currently has a consensus rating of “Buy” and an average target price of $165.65.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 4th. The medical equipment provider reported $2.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.06 by $0.05. The company had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.08 billion. Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.30 earnings per share. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 4.8 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 30th. Investors of record on Monday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Friday, March 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.57%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 12.20%.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products.
Featured Story: What member countries make up the G-20?
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.